ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma - Wikidata - wikimedia - TriplyDB

ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma

ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma

http://www.wikidata.org/entity/Q24645750

about

Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer Metastasis Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9.ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis.ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression.A disintegrin and metalloproteinase 9 is involved in ectodomain shedding of receptor-binding cancer antigen expressed on SiSo cells.The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression Molecular characteristics of pancreatic ductal adenocarcinoma The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?The G Protein-Coupled Receptor RAI3 Is an Independent Prognostic Factor for Pancreatic Cancer Survival and Regulates Proliferation via STAT3 Phosphorylation.New tumor-associated antigen SC6 in pancreatic cancer.Molecular prognostic factors in patients with pancreatic cancer.Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.Loss of the metalloprotease ADAM9 leads to cone-rod dystrophy in humans and retinal degeneration in mice.ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas MicroRNA-126 overexpression rescues diabetes-induced impairment in efferocytosis of apoptotic cardiomyocytes.Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer.Regulators of epithelial mesenchymal transition in pancreatic cancer.Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy.Pancreatic cancer: current understanding of molecular and genetic aetiologies.ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype.Overexpression of ADAM9 Promotes Colon Cancer Cells Invasion.Loss of tumor suppressor miR-126 contributes to the development of hepatitis B virus-related hepatocellular carcinoma metastasis through the upregulation of ADAM9.High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage I non-small cell lung cancer.ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death.MicroRNA-154/ADAM9 axis inhibits the proliferation, migration and invasion of breast cancer cells.Loss of ADAM9 expression impairs β1 integrin endocytosis, focal adhesion formation and cancer cell migration.Collagen XVII/laminin-5 activates epithelial-to-mesenchymal transition and is associated with poor prognosis in lung cancer.Sorting nexin 9 (SNX9) regulates levels of the transmembrane disintegrin and metalloproteinase (ADAM)-9 at the cell surface.Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression.

P2860

Q26767150-97DA9F8B-EDD4-488B-B314-24C649D844D0 Q27333563-C547795F-25BA-4626-9EFB-C7D448C70A45 Q28255938-BED2BD97-C0E1-4C73-9E05-FB7046EC7362 Q30481528-5DB4668C-4E46-43AC-8C39-0613DCB10A65 Q33346972-4F2FC0D3-4187-4AEB-8F52-5725363D1799 Q34079881-DFDB6365-D969-4248-A0B5-D75471936E68 Q34646724-085DF994-64D2-4969-BD77-922F3F179789 Q34745252-0E78F92D-B63D-46CB-8CF0-F105C3803C00 Q35206311-7963F597-D226-494F-9A89-CD5E3E2B0F5A Q36257567-D967637D-8DD9-4BBD-96BC-D7D40390A765 Q36503356-69A47A2E-59A6-455F-A80A-292E24C90E2F Q37004734-4C848197-0345-454E-9684-726A6D52244F Q37176648-84744DDB-490D-4BC6-8F9C-B1DB43AFA28A Q37189157-A075FB83-8A1C-4786-BA87-C4E678406253 Q37286187-6B6136C2-43C0-49B8-9AEF-70652FF8189B Q37403068-21E302EA-8906-4F7F-8194-6FFAF4BE4B17 Q37412311-ADE52A76-8FF3-443D-8926-C4401F72EB7D Q37885319-4B02F6D0-FE07-4EDB-9A4B-42B74B6BD8FE Q38039076-BFE115CC-8597-4569-BBB7-B9BB4D794174 Q38478670-66ECCE0E-7CE1-4504-8B38-16BAAD433C76 Q38540431-EC283B63-83D7-4D81-A07D-026B110BF8BF Q38694788-ADD1ABAE-9B9E-4F30-ACA0-85ADDCB524E0 Q39916438-225DBB2F-02AB-4A99-BCA3-E55C87856EC4 Q40149856-81D04532-26C0-4265-991F-74DC7655A80A Q42149506-3B6957BC-4AD0-4067-B150-85A7D1B9074F Q46238472-EC58B7A9-20AD-452A-B04E-EEBFB9750170 Q47143534-B040421C-F8CE-49A7-B755-79E025C05A75 Q47590431-88C55535-652F-45AB-B2BB-87DBE5AB571A Q49181001-DD7CC23C-A8EE-4BD4-92D6-7DC2ABFD4B75 Q52603837-129AAA2A-69E3-45DD-BE11-B84D994C655E Q53134470-E91F5986-4935-449C-BAE9-261CC0608015 Q54222811-4BEFC4CB-A521-4543-B951-085A758E228F

P2860

ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma

http://www.wikidata.org/entity/Q24645750

description

2004 nî lūn-bûn

@nan

2004 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մարտին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

ADAM9 expression in pancreatic ...... actor in ductal adenocarcinoma

@ast

ADAM9 expression in pancreatic ...... actor in ductal adenocarcinoma

@en

ADAM9 expression in pancreatic ...... actor in ductal adenocarcinoma

@nl

type

label

ADAM9 expression in pancreatic ...... actor in ductal adenocarcinoma

@ast

ADAM9 expression in pancreatic ...... actor in ductal adenocarcinoma

@en

ADAM9 expression in pancreatic ...... actor in ductal adenocarcinoma

@nl

prefLabel

ADAM9 expression in pancreatic ...... actor in ductal adenocarcinoma

@ast

ADAM9 expression in pancreatic ...... actor in ductal adenocarcinoma

@en

ADAM9 expression in pancreatic ...... actor in ductal adenocarcinoma

@nl

P1433

Q24645750-59D5433A-DFA8-4661-91BC-EC4DFD83CBA2

P1476

Q24645750-069BB469-7A08-4884-9529-EDB6AB1DB5DD

P2093

Q24645750-0491C440-D968-42EE-8C74-6F4A4A918D43

Q24645750-0D57F925-B4CE-471E-AE48-FF678432C17A

Q24645750-2B4509ED-380B-48AF-B5B1-33C927017B90

Q24645750-45DDBFB4-BBDF-4739-A8A3-05A090DEE2F7

Q24645750-6D5427F9-93D4-41A8-B4D6-69D213658561

Q24645750-706EE414-E9BE-4440-80EE-B6955117AFAF

Q24645750-92807C4D-D570-4EE7-9324-54789AFBC950

Q24645750-A397FC05-261F-49F3-BBEE-A102E683C553

Q24645750-C938C99D-3896-42C3-9FBB-CA9ACBC33B0D

Q24645750-D527590F-F567-45E4-BB9D-C559AA0044CE

P2860

Q24645750-18D0DCB8-236A-4B79-87D2-1352EEDE7B3B

Q24645750-1A29FB69-1673-407B-9E79-8153AB155675

Q24645750-201DC87C-F7F9-4D7C-88D8-B17BF0C78037

Q24645750-209199E9-CF8D-4215-AD21-72A7BEEFF72C

Q24645750-368F09E6-BE53-4246-B1D0-362A6A707667

Q24645750-464663EE-E434-4132-A0A3-D2C50D7A22F9

Q24645750-4913E7A0-29BB-4815-9793-50CB9788A55A

Q24645750-7D47B476-2D80-47E8-A77B-57C61A0DA948

Q24645750-904886B4-E2AA-4B41-8112-65BEA9800D12

Q24645750-909015DB-1ECF-4492-A9BA-ED0789505AD6

P2888

Q24645750-9B5D4550-F6B0-41F8-88AA-F3606B6BCAE6

P304

Q24645750-70BB89E6-B800-4918-96EF-0C3DD0C5A864

P31

Q24645750-BB8F4B46-A9F9-4318-86EC-4FA7203C094D

P3181

Q24645750-1E503766-5C48-4E4A-A3B4-77FDEEB2F7D0

P356

Q24645750-D87CC89E-3A38-495D-A371-DBF5B982DAD7

P407

Q24645750-41103F98-FA81-47A1-93AE-8159D26B658F

P433

Q24645750-D0914CF3-9DD0-49B4-B10D-4308D73E8538

P478

Q24645750-6F5302CC-C5BF-4829-8017-ECBB53D28424

P577

Q24645750-D615CB05-FDFF-45DF-83B6-A80A992E7677

P5875

Q24645750-559D0660-DC7E-4460-B70B-65DB84D7396B

P6179

Q24645750-CB093495-877F-47EA-946B-835E479D8772

P698

Q24645750-7AFD31F3-6961-4A52-A528-267257538E74

P921

Q24645750-84A7C1FB-6F9A-452D-B618-5E9BD80EDF15

P932

Q24645750-DDDFA90B-19B4-4555-8274-74AF96E09859

P3181

P356

P1433

British Journal of Cancer

P1476

ADAM9 expression in pancreatic ...... actor in ductal adenocarcinoma

@en

P2093

B Sipos

http://www.w3.org/2001/XMLSchema#string

C Pilarsky

http://www.w3.org/2001/XMLSchema#string

D Ockert

http://www.w3.org/2001/XMLSchema#string

F Dobrowolski

http://www.w3.org/2001/XMLSchema#string

G Klöppel

http://www.w3.org/2001/XMLSchema#string

H D Saeger

http://www.w3.org/2001/XMLSchema#string

H K Schackert

http://www.w3.org/2001/XMLSchema#string

H Kalthoff

http://www.w3.org/2001/XMLSchema#string

I Alldinger

http://www.w3.org/2001/XMLSchema#string

J Lüttges

http://www.w3.org/2001/XMLSchema#string

P2860

Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity

A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor.

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays

Expression of ADAM-9 mRNA and protein in human breast cancer

The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs

K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.

Role of integrins in cancer: survey of expression patterns.

ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling.

TACE and other ADAM proteases as targets for drug discovery.

P2888

P304

1053-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2617325

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.BJC.6601645

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8680463

http://www.w3.org/2001/XMLSchema#string

P6179

1002252303

http://www.w3.org/2001/XMLSchema#string

P698

14997207

http://www.w3.org/2001/XMLSchema#string

P921

P932

2409625

http://www.w3.org/2001/XMLSchema#string